85943-75-5

Basic information

• Product Name: Benzaldehyde, 5-(1,1-dimethylethyl)-2-hydroxy-3-nitro-
• CAS NO: 85943-75-5
• Molecular Formula: C11H13NO4
• Molecular Weight: 223.229
• Mol File: 85943-75-5.mol

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 5-(1,1-dimethylethyl)-2-hydroxy-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 5-(1,1-dimethylethyl)-2-hydroxy-3-nitro-(85943-75-5)
• EPA Substance Registry System: Benzaldehyde, 5-(1,1-dimethylethyl)-2-hydroxy-3-nitro-(85943-75-5)

Safety Data

• Hazardous Substances Data: 85943-75-5(Hazardous Substances Data)

Upstream product

• 2725-53-3 2-hydroxy-5-t-butylbenzaldehyde 

Downstream Products

• 1269761-67-2 C₃₆H₄₇N₃O₄ 
• 1269761-68-3 C₄₈H₆₂N₄O₅ 
• 1269761-70-7 C₇₂H₉₂N₆O₇ 
• 99758-66-4 5-(tert-butyl)-2-methoxy-3-nitrobenzaldehyde 
• 1269761-60-5 4-tert-butyl-2-(1,3-diphenylimidazolidin-2-yl)-6-nitrophenol 
• 1262020-31-4 C₁₉H₁₉NO₄ 
• 1262020-39-2 (Z)-2-benzylidene-7-nitro-5-tert-butyl-2,3-dihydrobenzofuran-3-ol 
• 85943-76-6 5-tert-butyl-2-hydroxyl-3-nitro-benzonitrile 
• 100373-31-7 5-tert-butyl-2-hydroxy-3-nitro-cis-cinnamic acid 
• 344907-68-2 (R,R)-N,N'-bis(3-nitro-5-tert-butylsalicylidene)-1,2-cyclohexanediamine 
• 100393-96-2 6-tert-butyl-8-nitro-coumarin 
• 100373-31-7 5-tert-butyl-2-hydroxy-3-nitro-trans-cinnamic acid 

Relevant articles and documents

Salicylaldehyde Hydrazones: Buttressing of Outer-Sphere Hydrogen-Bonding and Copper Extraction Properties

Salicylaldehyde hydrazones are weaker copper extractants than their oxime derivatives, which are used in hydrometallurgical processes to recover ～20% of the world's copper. Their strength, based on the extraction equilibrium constant Ke, can be increased by nearly three orders of magnitude by incorporating electron-withdrawing or hydrogen-bond acceptor groups (X) ortho to the phenolic OH group of the salicylaldehyde unit. Density functional theory calculations suggest that the effects of the 3-X substituents arise from a combination of their influence on the acidity of the phenol in the pH-dependent equilibrium, Cu2++2Lorg→[Cu(L-H)2]org+2H+, and on their ability to 'buttress' interligand hydrogen bonding by interacting with the hydrazone N-H donor group. X-ray crystal structure determination and computed structures indicate that in both the solid state and the gas phase, coordinated hydrazone groups are less planar than coordinated oximes and this has an adverse effect on intramolecular hydrogen-bond formation to the neighbouring phenolate oxygen atoms.

NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS

Heteroaryloxy-substituted benzoic acid amides of general formula I wherein the groups R1 to R7 as well as X and Y are defined according to claim 1, including the tautomers, the stereoisomers, the mixtures and the salts thereof. The compounds according to the invention are suitable for the treatment of respiratory complaints, particularly COPD and asthma.

7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases

The present invention provides compounds according to general formula (I) which are proposed for the treatment of respiratory complaints, particularly asthma and COPD.

Campestarenes: Novel shape-persistent Schiff base macrocycles with 5-fold symmetry

A simple 1-step procedure yields a family of easily modifiable, stable, conjugated Schiff base macrocycles with 5-fold symmetry mediated by 3-center hydrogen bonding.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1), wherein the groups R1 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for

Discovery and characterization of the N-phenyl-N′-naphthylurea class of p38 kinase inhibitors

An effort aimed at exploring structural diversity in the N-pyrazole-N′-naphthylurea class of p38 kinase inhibitors led to the synthesis and characterization of N-phenyl-N′-naphthylureas. Examples of these compounds displayed excellent inhibition of TNF-α production in vitro, as well as efficacy in a mouse model of lipopolysaccharide induced endotoxemia. In addition, perspective is provided on the role of a sulfonamide functionality in defining inhibitor potency.

Cytokine inhibitors

Disclosed are compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclos

1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION

Disclosed are compounds of formula (I), where Ar1, X, R3, R4, R5 and R6 are defined herein. The compounds of the invention inhibit production of cytokines and are thus useful for treating cytokine mediated diseases. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.